Monday, December 3, 2018

BeiGene to host investor meeting


Management discusses the Company’s data on Tislelizumab and Zanubrutinib presented at the American Society of Hematology (ASH) Annual Meeting at an Investor Meeting being held in San Diego, CA on December 3 at 11 pm.
at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.